Skip to content

Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome

The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00485368
Enrollment
17
Registered
2007-06-13
Start date
2004-01-31
Completion date
2006-09-30
Last updated
2007-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marfan Syndrome

Keywords

marfan syndrome, aortic root diameter

Brief summary

The purpose of this research is to assess the effects of a drug called perindopril on the aorta in people known to have Marfan Syndrome. The aorta is the major artery of the body that comes out of the heart and supplies blood to the body. We know that in people with Marfan Syndrome, the aorta is stiff and this stiffness results in its enlargement over many years. This enlargement of the aorta can be very serious. We know from treatment of other heart conditions that drugs of the same type as perindopril reduce stiffness of the arteries. This type of drug has never been tried in people with Marfan Syndrome.

Interventions

DRUGCoversyl (perindopril)

Sponsors

Baker Heart Research Institute
CollaboratorOTHER
The Alfred
CollaboratorOTHER
Bayside Health
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-40 * Diagnosis of Marfan Syndrome, on the basis of the Ghent Criteria

Exclusion criteria

* Age \<18, \>40 * Women of child-bearing potential not on adequate contraception * Serum creatinine of \>0.11 * A history of intolerance to ACEI * Patients on angiotensin receptor blockers * Blood pressure \>140/90mmHg * History of previous aortic surgery

Design outcomes

Primary

MeasureTime frame
aortic root diameter24 weeks

Secondary

MeasureTime frame
arterial stiffness24 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 6, 2026